T-cel and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation by Using Immunomagnetic Negative and Positive Selection Procedures
- Patients with the diagnosis of:
- De novo acute myeloid leukaemia in first or second remission.
- Secondary acute myeloid leukaemia in first or second remission supervening
after myelodysplastic syndrome or cytotoxic / immunosuppressive therapy.
- Acute lymphoblastic leukaemia in first or second remission.
- Myelodysplastic syndrome.
- Chronic myeloid leukaemia, patients who are candidate for SCT.
- Malignant lymphoma following relapse or first line therapy resistant.
- Aggressive mantle cell lymphoma in first complete remission.
- Age 18-65 years.
- WHO performance 0-1 (see appendix ).
- Availability of an HLA-identical sibling or HLA, A, B, DRB, DQB -identical VUD donor.
- Life expectancy > 3 months.
- Witnessed written informed consent.
- Patients with severe cardiac dysfunction (NYHA-classification II-IV)
- Patients with severe pulmonary dysfunction (vital capacity or diffusion < 70% of
- Patients with hepatic dysfunction, bilirubin or transaminases > 2.5 x upper normal
- Patients with renal dysfunction, serum creatinin > 150 umol/liter or clearance < 40
- Patients with a history of moderate ore severe CNS disturbances and psychiatric
- Prior treatment with chemotherapy, immunotherapy, radiation therapy or surgery within
the last 3 weeks before entering the study.
- Patients with active uncontrolled infections.
- Patients who are poor medical risks because of non malignant systemic disease.
- Patients with severe coagulopathy.
- Patients to be known HIV positive.